
MOTS-c raises AMPK signaling indirectly. Its described cellular action is to inhibit the folate cycle and the de novo purine biosynthesis tethered to it, and that inhibition leads to AMPK activation[1]. The proposed connector is an AMP-like purine intermediate; the best-characterized example is ZMP, the monophosphorylated derivative of AICAR, used in rat hepatocytes to activate AMPK[2]. That is a working model for MOTS-c, not a measured MOTS-c result. AMPK is the energy sensor that raises catabolic activity and shuts down biosynthetic pathways when energy status falls[3]. Outputs reported downstream of MOTS-c-driven AMPK activation include PGC-1α- and AMPK-dependent mitochondrial bioenergetics in skeletal muscle[4] and an AMPK–HIF-1α–PFKFB3 glycolytic program in pulmonary microvascular endothelial cells[5].
The mechanism chain, step by step

1. A purine intermediate accumulates and stands in for AMP. The best-characterized version of this step comes from AICAR rather than from MOTS-c. In rat hepatocytes, AICAR is phosphorylated to ZMP, which mimics both activating effects of AMP on AMPK — direct allosteric activation and increased phosphorylation by AMPK kinase — without perturbing cellular ATP, ADP or AMP[2]. The activation is site occupancy: ZMP binds the kinase’s AMP site, the same allosteric site AMP uses, so AMPK can be switched on without MOTS-c itself binding the kinase.
2. AMPK is switched on through two arms. One arm is allosteric, driven by an adenylate-like ligand; the other is covalent, phosphorylation of the α-subunit by an upstream kinase[2]. The phospho-AMPKα readout used in MOTS-c experiments captures the covalent arm[5]. A phospho-blot on its own reports that arm only; allosteric activation needs a separate activity measurement.
3. Active AMPK rewires metabolism. AMPK promotes ATP production by increasing the activity or expression of catabolic proteins and conserves ATP by switching off biosynthetic pathways[3]. In hepatocytes treated with AICAR, AMPK activation phosphorylated and inactivated HMG-CoA reductase and almost completely stopped fatty acid and sterol synthesis[2] — the downstream logic demonstrated with a pharmacological AMP mimetic, not with the peptide.
Why the indirect route matters
Three consequences follow from the signal being carried by a metabolite rather than by a receptor interaction.
The effect should track flux through one-carbon metabolism rather than occupancy of a surface receptor. If the signal is carried by one-carbon flux, the effect should track the cell’s nutrient and folate status, and dose-response curves from different media would not be directly comparable. That is an inference from the proposed route, not a measured medium effect in the two source experiments[1][2].
AMPK activation is not evidence for a MOTS-c receptor. Because ZMP behaves as an AMP mimetic[2], the pathway described in 2015[1] predicts that any manipulation raising the same purine intermediate will produce a similar AMPK signature. None of the cited studies shows the peptide binding AMPK or its upstream kinase.
AICAR cannot serve as an independent control. AICAR is used to activate AMPK in intact cells precisely because it reliably raises ZMP[2] — the same final step MOTS-c is proposed to reach. An experiment using AICAR as a positive control confirms that the AMPK assay works; it does not separate the two mechanisms.
Reported outputs: AMPK-linked and AMPK-untested

Skeletal muscle mitochondria. In two transgenic mouse strains, MOTS-c treatment augmented muscle mitochondrial bioenergetic performance, and the effect depended on both PGC-1α and AMPK[4]. Respiratory protein content did not change appreciably, pointing to intrinsic mitochondrial changes rather than an increase in mitochondrial volume. The same study reported lower mitochondrial ROS emission and ROS-related protein damage, with RNA sequencing suggesting shifts across redox handling, mitochondrial integrity and OXPHOS efficiency[4].
ACC phosphorylation and glucose uptake. Neither readout has been reported after MOTS-c in the studies cited here, so two links in this chain remain untested. A phospho-ACC measurement would test whether the kinase output reaches the ACC substrate rather than stopping at phospho-AMPKα, and a glucose-uptake or GLUT4 assay would test whether transport changes rather than only organism-level insulin sensitivity. Those are potential tests, not findings: the mouse insulin-sensitivity data[1] and the endothelial glycolysis data[5] do not substitute for them.
Glycolysis in endothelial cells. In a cardiopulmonary-bypass lung injury model, MOTS-c pretreatment increased glycolytic flux, restored PFKFB3 expression, reduced oxidative stress and suppressed ferroptosis in pulmonary microvascular endothelial cells. Phosphorylated AMPKα and HIF-1α were elevated, and genetic or pharmacological inhibition of PFKFB3 abolished the protection[5]. That establishes a requirement for PFKFB3 and involvement of the AMPK–HIF-1α pathway; it is not loss-of-function proof that AMPK or HIF-1α carries the effect.
Nuclear gene regulation. MOTS-c translocates to the nucleus after metabolic stress and regulates nuclear gene expression in an AMPK-dependent manner, including genes carrying antioxidant response elements, and it interacts with ARE-regulating transcription factors such as NRF2[6]. That places AMPK upstream of at least part of MOTS-c’s transcriptional output.
Whole-body metabolism and physical capacity. In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity[1]. Intermittent treatment begun at 23.5 months increased physical capacity and healthspan, and treatment enhanced physical performance in young (2 months), middle-aged (12 months) and old (22 months) animals[7]. Neither report tested AMPK dependence for these endpoints, so they are MOTS-c outcomes rather than demonstrated AMPK outputs.
Which model supports which claim
| Claim | Model system | Source |
|---|---|---|
| Folate cycle and de novo purine synthesis inhibition leads to AMPK activation | Cell-level actions; mouse treatment effects reported separately | [1] |
| ZMP mimics AMP to activate AMPK allosterically and by phosphorylation | Rat hepatocytes, AICAR tool compound | [2] |
| MOTS-c enters the nucleus and regulates ARE genes in an AMPK-dependent way | Cell models under glucose restriction | [6] |
| Muscle mitochondrial bioenergetics require PGC-1α and AMPK | Two transgenic mouse strains | [4] |
| Glycolysis runs through AMPK–HIF-1α–PFKFB3; ferroptosis suppressed | Endothelial cells, in vivo models, patient plasma sampling | [5] |
| Physical performance and healthspan | Mice, 2 to 23.5 months; AMPK dependence not assessed | [7] |
| Exercise raises endogenous MOTS-c in muscle and circulation | Humans, observational | [7] |
| No change in arterio-venous difference across an exercising leg | Humans, observational | [4] |
| Lower plasma MOTS-c in patients with lung injury after cardiopulmonary bypass | Humans, observational, 107 patients | [5] |
Human data are observational only
None of the studies cited here reports giving MOTS-c to people. The human content is measurement of endogenous peptide.
Exercise induces endogenous MOTS-c expression in skeletal muscle and in the circulation[7]. A separate study found increased interstitial MOTS-c during one-legged knee extensor exercise but no change in the arterio-venous difference across the leg, which the authors read as evidence that skeletal muscle may not be the source of circulating MOTS-c during exercise[4]. The two results measure different things — tissue expression versus veno-arterial balance — and leave the source of circulating MOTS-c unresolved.
Among 107 patients undergoing cardiopulmonary bypass, plasma MOTS-c concentrations were significantly reduced in patients with acute lung injury[5]. That is an association in a surgical cohort. It does not show that raising MOTS-c prevents or treats lung injury, and the design does not establish which came first.
What the evidence leaves open
- Site-resolved phosphorylation. The cited MOTS-c experiments report phospho-AMPKα but not which residue is phosphorylated[5], so a Thr172-resolved account remains an evidence gap rather than a finding.
- Metabolite values. The 2015 study links folate-cycle inhibition to AMPK activation but reports no ZMP or AICAR concentrations measured after treatment[1].
How to read a MOTS-c/AMPK experiment
Five checks, ordered by how quickly they change the conclusion.
- Is the upstream block measured, or assumed? A causal case for the folate-cycle route needs the metabolite side: the purine intermediate should rise after MOTS-c, and preventing its formation — or relieving the folate/purine block — should lower AMPK activation. That experiment is what would turn the AICAR parallel[2] into a MOTS-c result.
- Is the phospho-readout site-resolved? A site-specific blot or mass-spectrometry measurement is what says which residue changed; total phospho-AMPKα does not.
- Is AMPK dependence tested by loss of function, not just by an activator or inhibitor? The dependence evidence with a genetic handle comes from the muscle mitochondrial endpoint: in two transgenic mouse strains, the bioenergetic effect required both PGC-1α and AMPK[4]. For nuclear translocation the report is only that the transcriptional response is AMPK-dependent[6], with no method stated for it. A pharmacological activator or inhibitor alone cannot show that the peptide’s effect runs through AMPK; a deletion or knockdown of the kinase is the discriminating test.
- Which model produced the readout? Mouse performance and healthspan endpoints[7] and human plasma correlations[5] answer different questions and cannot substitute for each other.
- Does the tissue match the claim? Skeletal muscle is the proposed primary target[1]; the glycolytic data come from pulmonary microvascular endothelium in a bypass injury model[5] and do not transfer to muscle without direct measurement.
Related research: Retatrutide + MOTS-c Stack: Evidence Map (Not a Protocol); SS-31 vs MOTS-c: Two Different Approaches to Mitochondrial Research; What Are Mitochondrial-Derived Peptides? MOTS-c and Humanin Explained; What Is MOTS-c.
Research use only. MOTS-c and related research compounds are for laboratory investigation. This article contains no human or veterinary dosing, administration, compounding, diagnostic or purchasing guidance.
References
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, 2015)
- 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? (Corton JM, 1995)
- AMPK: a nutrient and energy sensor that maintains energy homeostasis (Hardie DG, 2012)
- MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner (Gudiksen A, 2026)
- MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury (Shen Z, 2025)
- The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress (Kim KH, 2018)
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, 2021)